Markers of survival and metastatic potential in childhood CNS primitive neuro-ectodermal brain tumours: an integrative genomic analysis.
Daniel Picard, Suzanne Miller, Cynthia E Hawkins...
https://pubmed.ncbi.nlm.nih.gov/22691720Actively Recruiting
All Genders
ID04794686
ETMR One: An International Registry and Research Platform for Children With Embryonal Tumor With Multilayer Rosettes
Led by Hackensack Meridian Health · Updated on 2026-06-02
100
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are collecting detailed medical information about a rare brain tumor called Embryonal Tumor with Multilayer Rosettes (ETMR) in children. The study aims to build and maintain a research database that includes data on how often the tumor occurs, patient details, tumor tissue characteristics, and responses to treatment. This will help improve understanding of ETMR and support future research. All patients with ETMR can join the registry regardless of their disease stage or treatment plan. The study collects epidemiologic, clinical, and molecular data after enrollment and follows patients over time to monitor outcomes. Although not required, patients are encouraged to receive a consensus therapy based on expert recommendations, which helps researchers evaluate treatment effects uniformly. Participants provide information through medical records and tumor tissue samples. The research team tracks survival and treatment responses over a 10-year period to assess how well the recommended therapy works. This observational study does not involve investigational treatments but collects valuable data to guide future care for children with ETMR.
CONDITIONS
Brief Title
ETMR One: An International Registry and Research Platform for Children With Embryonal Tumor With Multilayer Rosettes
Who Can Participate
All Genders
Eligibility Criteria
You may qualify if you...
- Patients of any age
- Histologically confirmed primary intracranial CNS Embryonal Tumor with Multilayer Rosettes confirmed by central review or local pathologist
- Tumor tissue possessing C19MC amplification
- Enrollment possible at any point following diagnosis
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Long-term Monitoring
Duration - Up to 10 years
Participants are followed longitudinally to obtain clinical outcome data over time.
Visits scheduled periodically to collect clinical outcome data
Trial Site Locations
Total: 1 location
1
Hackensack University Medical Center
Hackensack, New Jersey, United States, 07601
Actively Recruiting
Loading map...
Research Team
D
Derek Hanson, MD
K
Kellie Daniel, BA
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Embryonal tumor with abundant neuropil and true rosettes (ETANTR), ependymoblastoma, and medulloepithelioma share molecular similarity and comprise a single clinicopathological entity.
Andrey Korshunov, Dominik Sturm, Marina Ryzhova...
https://pubmed.ncbi.nlm.nih.gov/24337497LIN28A immunoreactivity is a potent diagnostic marker of embryonal tumor with multilayered rosettes (ETMR).
Andrey Korshunov, Marina Ryzhova, David T W Jones...
https://pubmed.ncbi.nlm.nih.gov/23161096The Lin28/let-7 axis regulates glucose metabolism.
Hao Zhu, Ng Shyh-Chang, Ayellet V Segrè...
https://pubmed.ncbi.nlm.nih.gov/21962509Frequent amplification of a chr19q13.41 microRNA polycistron in aggressive primitive neuroectodermal brain tumors.
Meihua Li, Kyle F Lee, Yuntao Lu...
https://pubmed.ncbi.nlm.nih.gov/19962671